Becoming an Authorised Prescriber of MDMA or Psilocybin

Key Takeaways

• From 1 July 2023 Australia became the first country to reschedule MDMA for PTSD and psilocybin for treatment resistant depression, enabling prescribing by authorised psychiatrists.
• Reported figures put roughly 87 patients through MDMA-assisted therapy and 47 through psilocybin-assisted therapy as at September 2025, while more than 600 therapists have completed recognised training. The bottleneck is authorised prescribers.
• The pathway requires a specialist psychiatrist registered with the Medical Board, an evidence based clinical treatment protocol, approval from an NHMRC registered human research ethics committee and TGA authorisation, with RANZCP's training framework setting minimum expectations.
• State Schedule 8 permits, secure storage and sourcing obligations apply on top, and supervision settings changed again in July 2026.
• The TGA's May 2026 consultation findings on professional pathways signal that the framework is formalising, which favours psychiatrists who move while the field is still thin.

1. 1.In Brief
2. 2.The Scarcest Asset in the Sector
3. 3.What the Pathway Is Built From
4. 4.Where Applications Stall
5. 5.The Layer Nobody Budgets For
6. 6.Why the Window Favours Early Movers
7. 7.Frequently Asked Questions

From 1 July 2023 Australia became the first country in the world to reschedule MDMA and psilocybin so that authorised psychiatrists could prescribe them, MDMA for post-traumatic stress disorder and psilocybin for treatment resistant depression. Three years later the striking fact is not how many patients have been treated. It is how few. Reported figures put roughly 87 patients through MDMA-assisted therapy and 47 through psilocybin-assisted therapy as at September 2025, while more than 600 therapists are reported to have completed recognised training. Six hundred trained therapists and barely 130 treated patients is not a demand problem. It is a bottleneck, and the bottleneck is the authorisation.

In Brief

• Australia moved first in the world, and the prescribing lane runs exclusively through authorised psychiatrists.
• Reported patient numbers remain tiny against a reported pool of more than 600 trained therapists, which makes the authorised prescriber the scarcest asset in the sector.
• The pathway is built from four elements: specialist registration with the Medical Board, an evidence based clinical treatment protocol, approval from a human research ethics committee registered with the NHMRC and authorisation from the TGA.
• RANZCP has published a training framework setting minimum expectations, and the TGA's May 2026 consultation findings show the professional pathways formalising.
• State Schedule 8 permits, secure storage and sourcing obligations sit on top of all of it, and supervision settings changed again in July 2026.

The Scarcest Asset in the Sector

Every emerging treatment market has a choke point, and in Australian psychedelic-assisted therapy it is not capital, not premises and not therapists. It is the psychiatrist who holds the authorisation. Reported average charges of around 30,000 dollars for a three dose MDMA program tell you what the market already knows: capacity is scarce, and the person who controls the prescribing controls the clinic. For a psychiatrist weighing whether to build in this space, that scarcity is the commercial argument. The professional question is different, and it starts with what the pathway actually asks of you.

What the Pathway Is Built From

The authorised prescriber pathway has four load bearing elements. You must be a specialist psychiatrist registered with the Medical Board. You need an evidence based clinical treatment protocol. That protocol needs approval from a human research ethics committee registered with the NHMRC. And you need authorisation from the TGA. Alongside those, RANZCP has published a training framework setting minimum expectations for the psychiatrists who do this work.

Listed like that, it sounds like a checklist. It is not. Each element is a document, a committee or a regulator with its own standards and its own view of what good looks like, and the elements interact. The protocol shapes what the ethics committee will approve, the ethics approval frames what the TGA is asked to authorise and every weak joint in that chain surfaces later as a question you answer from a worse position. The psychiatrists who move smoothly through the pathway treated it as one designed application, not four separate hurdles.

Where Applications Stall

The stall points are rarely clinical competence. They are structural. A protocol drafted with a research mindset when the committee is reading it for a treatment service. An ethics approval sought from the wrong committee for the model proposed. A sequencing choice that puts a gap in front of the TGA. None of these is fatal, but each costs months, and in a field where reported patient numbers are still double digits, months are market position.

There is also a quieter risk. What you put in front of a regulator becomes part of your regulatory history. Frank advice about your model, your evidence base and your weak points before you lodge is exactly what legal professional privilege exists for, and no training course or consultant can give you that.

The Layer Nobody Budgets For

TGA authorisation is the Commonwealth's answer. The states have their own. Schedule 8 permits, secure storage and sourcing obligations all apply to these substances, and they attach to the practical realities of your clinic: where the drug sits, who can handle it, how it arrives. Supervision settings changed again in July 2026, which is the clearest possible signal that this layer is not settled. A prescriber whose Commonwealth authorisation is immaculate can still be non-compliant at state level, and the state layer is where inspections happen.

Why the Window Favours Early Movers

In May 2026 the TGA released targeted consultation findings on professional pathways for psychedelic-assisted therapy training, covering eligibility by professional registration, clinical experience and competency. Read that as a weather report: the framework is formalising. Fields like this reward the practitioners who establish themselves while the requirements are still forming, because they become the reference points the settled rules are written around. The psychiatrists who are authorised, operating and credible when the framework hardens will be in a different position from those who waited for certainty that never quite arrives.

Frequently Asked Questions

Who can become an authorised prescriber of MDMA or psilocybin?

The pathway is built around specialist psychiatrists registered with the Medical Board. The other elements, the protocol, the ethics approval and the TGA authorisation, attach to that foundation, and RANZCP's training framework sets minimum expectations for the clinical side.

How long does the pathway take?

It depends on how well the elements are sequenced and how the protocol and ethics steps are handled. The stall points are structural rather than clinical, and the difference between a designed application and an improvised one is measured in months.

Does TGA authorisation let me start treating patients?

Not by itself. State Schedule 8 permits, secure storage and sourcing obligations apply on top, and supervision settings changed again in July 2026. The state layer has to be built into the plan, not discovered after the Commonwealth approval.

Is there actually a market for this?

Reported average charges are around 30,000 dollars for a three dose MDMA program, and the Department of Veterans' Affairs has announced a reported 740 million dollar veterans rehabilitation package that includes support for psychedelic-assisted therapy for eligible veterans with PTSD, with funding from 2025-26. The demand signals are serious. The constraint is authorised capacity.

What should I do before starting an application?

Understand the whole pathway, including the state layer, before you commit to any single step. The order in which you approach the elements shapes everything downstream, and that design work is best done under privilege.

Weighing the authorised prescriber pathway or building the clinic around it? Visit our psychedelic clinic page, Contact Astris Law for a fixed fee consultation or call (07) 3519 5616.

This article is for general information purposes only and does not constitute legal advice and should not be relied on as such. While we take reasonable care to ensure the accuracy of the information provided, we make no representations or warranties as to its completeness, currency or reliability. We accept no liability for any loss or damage arising directly or indirectly from the use of, or reliance on, this website's content. You should always seek professional advice tailored to your specific circumstances before acting on any information in this article. Liability limited by a scheme approved under Professional Standards Legislation.